Document:

Accelerated
Clinical Trial Agreement

 

This
Accelerated Clinical Trial (ACTA) Agreement (“Agreement”) is made as of April 10, 2018 (“Effective Date”)
by and between Cancer Center of Kansas, P.A. (“Institution”), having an address at 818 N. Emporia, Suite 403, Wichita,
KS 67214, and Cancer Insight, LLC, a limited liability company having its principal place of business at 110 East Houston Street,
Floor Seven, San Antonio, TX 78205 (“CRO”). CRO and Institution are herein referred to collectively as “Parties.”
Individually, each of CRO and Institution is a “Party.”

 

WHEREAS,
CRO has been engaged by BriaCell Therapeutics Corp. (the “Sponsor”) to arrange and administer a multi-center clinical
trial funded by Sponsor to determine the safety and efficacy of Sponsor’s product;

 

WHEREAS,
Sponsor is a for-profit organization that intends to conduct a sponsored multi-center clinical trial, described in 1.1 below,
involving the use of certain diagnostic(s), drug(s), devices(s), or biologic(s) provided by Sponsor and desires that Institution
participate in such clinical trial;

 

WHEREAS,
Institution, Sponsor and CRO have agreed to use the ACTA, to accelerate the process of translating laboratory discoveries
into treatments for patients, to engage communities in clinical research efforts, and to train a new generation of clinical and
translational researchers;

 

WHEREAS,
the Institution has appropriate facilities and personnel with the qualification, training, knowledge, and experience necessary
to conduct such a clinical trial; and

 

WHEREAS,
the Study contemplated by this Agreement is of interest and benefit to Institution, Sponsor and CRO, and will further the
instructional and research objectives of Institution in a manner consistent with its status as a research and health care institution;

 

NOW,
THEREFORE, in consideration for the mutual promises made in this Agreement and for valid consideration, the Parties agree
as follows:

 

1.
Scope of Agreement

 

1.1.
Institution will undertake a sponsored multi-center clinical trial (“Study”) described in the protocol entitled “A
Phase I/IIa Rollover Study of the Whole-Cell Vaccine BriaVaxTM in Metastatic or Locally Recurrent Breast Cancer Patients
in Combination with Ipilimumab or Pembrolizumab,” and having a protocol designation of BRI-ROL-001, which is incorporated
herein as Exhibit A (“Protocol”). Institution will use its reasonable efforts to only recruit subjects in accordance
with the Protocol. The Study will be conducted by the Institution under the direction of Shaker Dakhil, M.D., an employee of Institution
(“Principal Investigator”).

 

1.2.
In the event of any conflict between the terms and conditions of this Agreement and the Protocol or between this Agreement and
any of its Exhibits, the terms and conditions of the Protocol shall control with respect to matters of the clinical conduct of
the Study, and the terms of this Agreement shall control with respect to all other matters.

 

    	1

    	 

    

 

1.3.
Unless otherwise agreed to by the Parties, Sponsor and/or CRO will provide to Institution on a timely basis, without charge, the
required quantities of properly-labeled Sponsor drug(s) or biologics(s) (“Study Drug”) and/or device(s) (“Study
Device”) and other materials (e.g., Investigator’s Brochure, handling and storage instructions, and, if applicable,
placebo) necessary for Institution to conduct the Study in accordance with the Protocol. Unless stated otherwise in writing by
Sponsor, all such items are and will remain the sole property of Sponsor until administered or dispensed to Study subjects during
the course of the Study. Receipt, storage, and handling of Study Drug or Study Device will be in compliance with all applicable
laws and regulations, the Protocol, and CRO’s or Sponsor’s instructions.

 

1.4.
CRO and Institution shall comply with and conduct all aspects of the Study in compliance with all applicable federal, state, and
local laws and regulations, including generally accepted standards of good clinical practice as adopted by current FDA regulations
and statutes and regulations of the U.S. Government relating to exportation of technical data, computer software, laboratory prototypes,
and other commodities as applicable to academic institutions. Institution will only allow individuals who are appropriately trained
and qualified to assist in the conduct of the Study.

 

1.5.
Institution shall obtain IRB approval for this Study and proof thereof shall be provided to CRO. Initiation of the Protocol and
Institution’s obligation to conduct the Study shall not begin until IRB approval is obtained. Institution shall obtain from
each subject, prior to the subject’s participation in the Study, a signed informed consent and necessary authorization to
disclose health information to CRO and/or Sponsor in a form approved in writing by the IRB or a waiver of consent as directed
by the IRB and further provided that the informed consent is consistent with Institution’s policies.

 

1.6.
Institution shall promptly inform Sponsor of any urgent safety measures as instructed in the Protocol or breaches of the Protocol
of which Institution becomes aware.

 

1.7.
Institution acknowledges CRO’s right to assign or transfer, in whole or in part, with notice to Institution, any of its
rights or obligations under this Agreement to the Sponsor or Sponsor’s designate.

 

2.
Payments

 

Sponsor
will provide financial support for the Study and will provide such funds to CRO who will pay Institution in accordance with the
budget attached as Exhibit B (“Budget”) on a prorated basis, according to the actual work completed and any
non-cancelable obligated expenses, for subjects who are enrolled into the Study. The Parties acknowledge that the Budget amounts
represent an equitable exchange for the conduct of the Study in light of the professional time and expenses required for the performance
of the Study.

 

In
addition to other necessary routing information detailed in Exhibit B, each payment shall clearly reference the Study Protocol
Number and PI name.

 

For
administrative convenience, various Study contact information may be attached hereto and incorporated by reference as Exhibit
C, entitled, “Administrative & Study Points of Contact.”

 

The
Institution’s tax identification number is: 48-1181579

 

    	2

    	 

    

 

3.
Confidentiality

 

3.1.
It is anticipated that in the performance of this Agreement, Sponsor and/or CRO on behalf of Sponsor may need to disclose to Institution
information which is considered confidential. The rights and obligations of the Parties with respect to such information are as
follows:

 

“Confidential
Information” refers to information of any kind which is disclosed to the Institution by Sponsor and/or CRO on behalf of
Sponsor for purposes of conducting the Study or Data (as defined below in Section 4) which:

 

a)
by appropriate marking, is identified as confidential and proprietary at the time of disclosure;

 

b)
if disclosed orally, is identified in a marked writing within thirty (30) days as being confidential.

 

Sponsor
and/or CRO on behalf of Sponsor will make reasonable efforts to mark Confidential Information as stated in (a) and (b) above.
However, to the extent such marking is not practicable, then in the absence of written markings, information disclosed (written
or verbal) that a reasonable person familiar with the Study would consider it to be confidential or proprietary from the context
or circumstances of disclosure shall be deemed as such.

 

Notwithstanding
the foregoing, Data and results generated in the course of conducting the Study are not Confidential Information for publishing
purposes in accordance with Section 9 of this Agreement. Institution agrees, for a period of five (5) years following the termination
or expiration of this Agreement, to use reasonable efforts, no less than the protection given their own confidential information,
to use Confidential Information received from Sponsor and/or CRO on behalf of Sponsor in accordance with this Section.

 

Institution
agrees to use Sponsor’s Confidential Information solely as allowed by this Agreement, and for the purposes of conducting
the Study. Institution agrees to make Sponsor’s Confidential Information available only to those of its, or its affiliated
hospitals’ employees, IRB members, personnel, agents, consultants, and vendors, and approved subcontractors, as applicable,
who require access to it in the performance of this Study, and are subject to similar terms of confidentiality.

 

3.2.
The obligation of nondisclosure does not apply with respect to any of the Confidential Information that:

 

	 	a)	is
    or becomes public knowledge through no breach of this Agreement by Institution;
	 	 	 
	 	b)	is
    disclosed to Institution by a third party entitled to disclose such information without known obligation of confidentiality;
	 	 	 
	 	c)	is
    already known or is independently developed by Institution without use of Sponsor’s Confidential Information as shown
    by Institution’s contemporaneous written records;
	 	 	 
	 	d)	is
    necessary to obtain IRB approval of Study or required to be included in the written information summary provided to Study
    subject(s) and/or informed consent form;
	 	 	 
	 	e)	is
    released with the prior written consent of the Sponsor; or
	 	 	 
	 	f)	is
    required to support the medical care of a Study Subject.

 

3.3.
Institution may disclose Confidential Information to the extent that it is required to be produced pursuant to a requirement of
applicable law, IRB, government agency, an order of a court of competent jurisdiction, or a facially valid administrative, Congressional,
or other subpoena, provided that Institution, subject to the requirement, order, or subpoena, promptly notifies Sponsor. To the
extent allowed under applicable law, Sponsor may seek to limit the scope of such disclosure and/or seek to obtain a protective
order. Institution will disclose only the minimum amount of Confidential Information necessary to comply with law or court order
as advised by Institution’s legal counsel.

 

    	3

    	 

    

 

3.4.
No license or other right is created or granted hereby, except the specific right to conduct the Study as set forth by Protocol
and under terms of this Agreement, nor shall any license or other right with respect to the subject matter hereof be created or
granted except by the prior written agreement of the Parties duly signed by their authorized representatives.

 

3.5.
Upon Sponsor’s and/or CRO’s written request, Institution agrees to return all Confidential Information supplied to
it by Sponsor and/or CRO on behalf of Sponsor at Sponsor’s expense pursuant to this Agreement except that Institution may
retain such Confidential Information in a secure location for purposes of identifying and satisfying its obligations and exercising
its rights under this Agreement.

 

3.6
Institution may disclose the existence of this Agreement and any additional information necessary to ensure compliance with applicable
Federal, State and Institutional policies, regulations, and laws.

 

4.
Data Use/Ownership

 

“Data”
shall mean all data and information generated by Institution as a result of conducting the Study in accordance with the IRB approved
Protocol. Data does not include original Study subject or patient medical records, research notebooks, source documents, or other
routine internal documents kept in the Institution’s ordinary course of business operations, which shall remain the sole
and exclusive property of the Institution or medical provider. Sponsor owns and has the right to use the Data in accordance with
the signed informed consent and authorization form, applicable laws, and the terms of this Agreement. Notwithstanding any licenses
or other rights granted to Sponsor herein, but in accordance with the confidentiality and publication sections herein, Institution
shall retain the right to use the Data and results for its publication, IRB, regulatory, legal, clinical, educational, and internal
research purposes.

 

5.
HIPAA/HIPAA Privacy

 

5.1.
Institution shall comply with applicable laws and regulations, as amended from time to time, including without limitation, the
Health Insurance Portability and Accountability Act of 1996 and its implementing regulations (HIPAA) with respect to the collection,
use, storage, and disclosure of Protected Health Information (PHI) as defined in HIPAA. CRO and Sponsor, through its agreement
with CRO, shall collect, use, store, access, and disclose PHI collected from Study subjects only as permitted by the IRB approved
informed consent form or HIPAA authorization form obtained from a Study subject. Sponsor will collect, use, store, and disclose
any Subject Material, defined in Section 15, it receives only in accordance with the informed consent form and, in any event,
will not collect, use, store, or disclose any PHI attached to or contained within the Subject Material in any manner that would
violate this Section of the Agreement.

 

Institution
acknowledges that, pursuant to Section 111 of the Medicare, Medicaid, and SCH IP Extension Act of 2007 (“MMSEA”),
Sponsor has an obligation to submit certain reports to the Centers for Medicare & Medicaid Services with respect to Medicare
beneficiaries who participate in the Study and experience a research injury for which diagnosis or treatment costs are incurred.
Sponsor and CRO recognize that each party is subject to laws and regulations protecting the confidentiality of research subject
information. Accordingly: (1) Institution agrees upon prior written request to provide to Sponsor, or CRO as designated by Sponsor,
certain identifiable patient information required by MMSEA for Study subjects who are Medicare beneficiaries and incur medical
costs in association with a research injury and whose costs are reimbursed by Sponsor pursuant to this Agreement; and (2) Institution
further agrees to otherwise cooperate with Sponsor (and CRO as designated by Sponsor) to the extent necessary for Sponsor to meet
its MMSEA reporting obligations.

 

    	4

    	 

    

 

5.2.
CRO’s ability to review the Study subjects’ Study-related information contained in the Study subject’s medical
record shall be subject to reasonable safeguards for the protection of Study subject confidentiality and the Study subjects’
informed consent form or HIPAA authorization form.

 

5.3.
Neither CRO, nor Sponsor through its agreement with CRO, shall attempt to identify, or contact, any Study subject unless permitted
by the informed consent form.

 

6.
Record Retention

 

As
applicable by law, Institution shall retain and preserve a copy of the Study records for the longer of:

 

	 	a)	two
    (2) years after a marketing authorization for Study Drug, or Study Device has been approved for the indication for which it
    was investigated or Sponsor has discontinued research on the Study Drug or Study Device;
	 	 	 
	 	b)	such
    longer period as required by federal regulatory requirements; or
	 	 	 
	 	c)	as
requested by Sponsor at Sponsor’s reasonable storage expense.

 

7.
Monitoring and Auditing

 

7.1.
Site visits by Sponsor, CRO and/or another authorized designee (e.g., Study monitor) will be scheduled in advance for times mutually
acceptable to the Parties during normal business hours. Sponsor’s, CRO’s and/or authorized designee’s access
is subject to reasonable safeguards to ensure confidentiality of medical records and systems.

 

7.2.
Upon becoming aware of an audit or investigation by a regulatory agency with jurisdiction over the Study, Institution agrees to
provide Sponsor with prompt notice of the auditor investigation. If legally permissible or allowable by the regulatory agency
and permissible in accordance with the Institution’s policy, Sponsor may be available or request to be present with approval
from auditor during such audit, but Sponsor will not alter or interfere with any documentation or practice of Institution. Institution
shall be free to respond to any regulatory agency inquiries and will provide Sponsor with a copy of any formal response or documentation
to the regulatory agency regarding the Study.

 

8.
Inventions, Discoveries and Patents

 

8.1.
It is recognized and understood that certain existing inventions and technologies, and those arising outside of the research conducted
under this Agreement, are the separate property of Sponsor or Institution and are not affected by this Agreement, and neither
Sponsor nor Institution shall have any claims to or rights in such separate inventions and technologies.

 

    	5

    	 

    

 

8.2.
Any new patentable inventions, developments, or discoveries made during and in the performance of the Study (“Inventions”)
shall be promptly disclosed to Sponsor. Title to Inventions that necessarily use or necessarily incorporate Sponsor’s Study
Drug and/or Study Device shall reside with Sponsor (“Sponsor Inventions”). Institution shall assign all Sponsor Inventions
to Sponsor in writing. Title to Inventions other than Sponsor Inventions (“Other Inventions”) shall reside with Sponsor
if Sponsor personnel are the sole inventors, with Institution if Institution personnel are the sole inventors, and shall be held
jointly if both Institution and Sponsor personnel are inventors. Institution’s obligations under Sections 8.2 and 8.3 hereunder
shall be performed by its appropriate office with technology transfer responsibilities, if required by and in accordance with
Institution’s policies.

 

8.3.
To the extent that Institution owns sole or joint title in any such Other Inventions, Sponsor is hereby granted, without option
fee other than consideration of the Study sponsored herein and the reimbursement to Institution for patent expenses incurred prior
to or during the option period, an option to acquire an exclusive, worldwide, royalty-bearing license to Institution’s rights
to any Other Invention, which option shall extend for no more than ninety (90) days after Sponsor’s receipt of an Invention
disclosure from Institution (“Option Period”). Sponsor and Institution shall use their reasonable efforts to negotiate,
for a period not to exceed ninety (90) days after Sponsor’s exercise of such option, a license agreement satisfactory to
both parties (“Negotiation Period”). In the event Sponsor fails to exercise its option within the Option Period, or
Sponsor and Institution fail to reach agreement on the terms of such license within the Negotiation Period, Institution shall
have no further obligation to Sponsor under this Agreement with regard to the specific Other Invention.

 

8.4.
Institution shall retain a royalty-free, irrevocable license to use for its own internal noncommercial research, educational and
patient care purposes, all Sponsor Inventions or Other Inventions licensed or assigned to Sponsor here under.

 

8.5.
Nothing contained in this Agreement shall be deemed to grant either directly by implication, estoppel, or otherwise any license
under any patents, patent applications, or other proprietary interest to any other inventions, discovery or improvement of either
Sponsor or Institution.

 

8.6.
CRO and Institution agree that the provisions of this Agreement are intended to be interpreted and implemented so as to comply
with all applicable federal laws, rules, and regulations, including without limitation the requirements of Rev. Proc. 2007-47;
provided, however, if it is determined by the Internal Revenue Service or any other federal agency or instrumentality (the “Government”)
that the provisions of this Agreement are not in such compliance, then those parties agree to modify the provisions and the implementation
of this Agreement so as to be in compliance with all applicable federal laws, rules, and regulations as determined by the Government.

 

9.
Publication

 

9.1.
Institution shall be free to publish, present, or use any Data and results arising out of its performance of the Protocol (individually,
a “Publication”). At least thirty (30) days prior to submission for Publication, Institution shall submit to Sponsor
for review and comment any proposed oral or written Publication (“Review Period”). Institution will consider any such
comments in good faith but is under no obligation to incorporate Sponsor’s suggestions. The Review Period for abstracts
or poster presentations shall be thirty (30) days. If during the Review Period, Sponsor notifies Institution in writing that:
(i) it desires patent applications to be filed on any inventions disclosed or contained in the disclosures, Institution will defer
Publication for a period not to exceed sixty (60) days, to permit Sponsor to file any desired patent applications; and (ii) if
the Publication contains Sponsor’s Confidential Information as defined in Section 3 and Sponsor requests Institution in
writing to delete such Sponsor’s Confidential Information, the Institution agrees to delete such Sponsor’s Confidential
Information only to the extent such deletion does not preclude the complete and accurate presentation and interpretation of the
Study results.

 

    	6

    	 

    

 

9.2.
The Parties agree that this Study is a multi-center clinical trial. Therefore, Institution agrees that the first Publication of
the results of the Study shall be made in conjunction with the presentation of a joint multi-center Publication of the Study results
with the Principal Investigators from all sites contributing Data, analyses, and comments. However, Institution may publish the
Data and Study results individually in accordance with this Section 9 upon first occurrence of one of the following: (i) multi
center Publication is published; (ii) no multi-center publication is submitted within eighteen (18) months after conclusion, abandonment,
or termination of the Study at all sites; or (iii) Sponsor confirms in writing there will be no multi-center Publication.

 

9.3.
If no multi-center Publication occurs within eighteen (18) months of the completion of the Study at all sites, upon request by
Institution, Sponsor will provide such Institution access to the aggregate Data from all Study sites.

 

9.4.
If the Institution, through its Principal Investigator, is identified to participate in the multi center Publication: (i) Institution
will have the opportunity to review the aggregate multi-center Data, upon request; and (ii) consistent with the International
Committee of Medical Journal Editors (ICMJE) regulations, Institution will have adequate opportunity to review and provide input
on any abstract or manuscript prior to its submission for Publication. Institution also retains the right, on behalf of its Principal
Investigator, to decline to be an author on any Publication.

 

10.
Use of Name

 

10.1.
Neither Institution nor CRO may use the name, trademark, logo, symbol, or other image or trade name of the other Party or their
employees and agents in any advertisement, promotion, or other form of publicity or news release or that in any way implies endorsement
without the prior written consent of an authorized representative of the other Party whose name is being used. Such approval will
not be unreasonably withheld.

 

10.2.
Institution and Sponsor understand that the amount of any payment made hereunder may be disclosed and made public by the other
party as required by law or regulation, including the Patient Protection and Affordable Care Act of 2010, provided that the disclosure
clearly designates the payment as having been made to Institution for research and not to the physician.

 

10.3.
Institution may acknowledge the Sponsor’s support, including but not limited to financial support as may be required by
academic journals, professional societies, funding agencies, and applicable regulations. Notwithstanding anything to the contrary
in this Agreement, Institution may publicly post information about the Study on Institution’s clinical trials directory/website.
Additionally, notwithstanding anything herein to the contrary, Institution shall have the right to post Sponsor’s and/or
CRO’s names, the Study title, and the Study period, and funding amount, on Institution publicly accessible lists of research
conducted by the Institution.

 

11.
Indemnification and Limitation of Liability

 

11.1
Sponsor’s indemnification obligations are outlined in a separate Letter of Indemnification, attached hereto as Exhibit
D.

 

    	7

    	 

    

 

11.2.
CRO expressly disclaims any liability in connection with the Study Drug or Study Device, including any liability for any claim
arising out of a condition caused by or allegedly caused by any Study procedures associated with such product except to the extent
that such liability is caused by the negligence, willful misconduct or breach of this Agreement by CRO.

 

11.3.
Institution shall have no obligation to indemnify CRO and CRO shall have no obligation to indemnify Institution.

 

12.
Subject Injury

 

Sponsor’s
subject injury obligations are outlined in Exhibit D.

 

13.
Insurance

 

13.1.
Institution shall, at its sole cost and expense maintain a policy or program of insurance or self- insurance at the level of at
least $1,000,000 per occurrence (or per claim) and $3,000,000 annual aggregate to support its obligations assumed in this Agreement.
However, if Institution is a public entity entitled to governmental immunity protections under applicable state law, then Institution
may provide liability coverage in accordance with any limitations associated with the applicable law.

 

13.2.
CRO shall maintain an insurance policy or a program of self-insurance at levels sufficient to support its obligations assumed
herein.

 

13.3.
Upon written request, either Party will provide evidence of its insurance or self-insurance acceptable to the other Party. A Party’s
inability to meet its insurance obligation constitutes material breach of this Agreement.

 

14.
Term and Termination

 

14.1.
This term of this Agreement shall commence upon the Effective Date and terminate upon the completion of the Parties’ Study-related
activities under the Agreement, unless terminated early as further described in this Section.

 

14.2.
CRO has the right to terminate this Agreement upon thirty (30) days prior written notice to the Institution. This Agreement may
be terminated immediately at any time for any reason by the Institution or CRO when, in their judgment or that of the Principal
Investigator, the Institution’s IRB, Scientific Review Committee, if applicable, or the Food and Drug Administration, it
is determined to be inappropriate, impractical, or inadvisable to continue, in order to protect the Study subjects’ rights,
welfare, and safety, or the IRB otherwise disapproves the Study. If for any reason Principal Investigator becomes unavailable
to direct the performance of the work under this Agreement, Institution shall promptly notify CRO. If the Parties are unable to
identify a mutually acceptable successor, this Agreement may be terminated by either Party upon thirty (30) days written notice.

 

14.3.
Notwithstanding the above a Party may, in addition to any other available remedies:

 

	 	a)	immediately
    terminate this Agreement upon the other Party’s material failure to adhere to the Protocol, except for deviation required
    to protect the rights, safety, and welfare of Study subjects; and/or

 

    	8

    	 

    

 

	 	b)	terminate
    this Agreement upon the other Party’s material default or breach of this Agreement, provided that the defaulting/breaching
    Party fails to remedy such material default, breach, or failure to adhere to the Protocol within thirty (30) business days
    after written notice thereof.

 

14.4.
In addition to the above, this Agreement may be terminated by Institution in the event of a material default or breach of this
Agreement by CRO, or by CRO in the event of a material breach of this Agreement by Institution, provided that the defaulting/breaching
party fails to remedy such material default or breach within thirty (30) business days after written notice thereof.

 

14.5.
In the event that this Agreement is terminated prior to completion of the Study, for any reason, Institution shall:

 

	 	a)	notify
    the IRB that the Study has been terminated;
	 	 	 
	 	b)	cease
    enrolling subjects in the Study;
	 	 	 
	 	c)	cease
    treating Study subjects under the Protocol as directed by CRO to the extent medically permissible and appropriate;
	 	 	 
	 	d)	terminate,
    as soon as practicable, all other Study activities; and
	 	 	 
	 	e)	furnish
    to CRO any required final report for the Study in the form reasonably acceptable to CRO.

 

Promptly
following any such termination, Institution will provide to CRO copies of Data collected pursuant to the Study Protocol. Upon
Sponsor’s or CRO’s written request, Institution shall provide to the requesting party, at Sponsor’s or CRO’s
expense, all Sponsor’s Confidential Information provided under this Agreement provided, however, that Institution may retain
such copy of Confidential Information for record keeping purposes, monitoring its obligations, and exercising its rights hereunder,
subject to Institution’s ongoing compliance with the confidentiality and non-use obligations set forth in this Agreement.

 

14.6.
If this Study is terminated early by either Party, the Institution shall be reimbursed for all work completed, on a pro rata basis,
and reasonable costs of bringing the Study to termination incurred through the date of termination, and for non-cancelable commitments
properly incurred through that date. Upon receipt of notice of termination, Institution will use reasonable efforts to reduce
or eliminate further costs and expenses and will cooperate with CRO to provide for an orderly wind-down of the Study.

 

14.7.
Subsections 1.4, 1.6, and 14.6, and Sections 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 (and the attached Letter of Indemnification), 12,
13, 15, 19 and 23, shall survive any termination or expiration of this Agreement, except that Section 3 shall survive for the
period stated in Section 3.1. Any provision of this Agreement that by its nature and intent remains valid after termination will
survive termination.

 

15.
Subject Material

 

15.1.
Subject Material means any biologic material of human origin including, without limitation, tissues, blood, plasma, urine, spinal
fluid, or other fluids derived from the Study subjects in accordance with and pursuant to the Protocol (“Subject Material”).

 

    	9

    	 

    

 

15.2.
Institution agrees to make the Subject Material available to the Sponsor in accordance with the Protocol for the purposes of the
Study. The Subject Material may be used by the Sponsor, central lab, or other contracted party only as allowed by the Study subject’s
informed consent form or pertinent institutional review board(s). Sponsor’s use of Subject Materials, other than as allowed
by the Study subject’s informed consent form, will require additional IRB review and approval.

 

16.
Subcontract

 

If
applicable, Institution has the right to subcontract to other sites to conduct the Study in accordance with the Protocol with
terms consistent with this Agreement with written approval of the Sponsor, which approval shall not be unreasonably withheld.
If Institution subcontracts any Study related duties, Institution shall contract with such subcontractors incorporating terms
substantially similar to the terms herein. Such subcontracts may be provided to the CRO upon written request.

 

The
Parties acknowledge and agree that the Sponsor and each of its affiliates is a third-party beneficiary to this Agreement.

 

17.
Notices

 

Any
notice, authorization, approval, consent or other communication will be in writing and deemed given:

 

	 	a)	Upon
    delivery in person;
	 	b)	Upon
    delivery by courier;
	 	c)	Upon
    delivery date by a nationally-recognized overnight delivery service such as FedEx.

 

If
to CRO:

 

Cancer
Insight, LLC

Attn:
Steven White

Chief
Operating Officer

110
E. Houston St.

San
Antonio, TX 78205

210-884-0810

swhite@cancerinsight.com

 

If
to Sponsor:

 

BriaCell
Therapeutics Corp.

820
Heinz Avenue

Berkeley,
CA 94710

Tel:
1-888-485-6340

Fax:
424-245-3719

 

If
to Institution:

 

Cancer
Center of Kansas, P.A.

Attn:
Shaker Dakhil, President

818
N. Emporia, Suite 403

Wichita,
KS 67214

Tel:
(316) 262-4467

 

    	10

    	 

    

 

With
a copy to Principal Investigator:

 

Cancer
Center of Kansas, P.A.

Attn:
Shaker Dakhil, M.D.

818
N. Emporia, Suite 403

Wichita,
KS 67214

Tel:
(316) 262-4467

 

18.
Independent Contractor

 

It
is mutually understood and agreed that the relationship between Institution and CRO is that of independent contractors. No party
shall represent itself as the agent, employee, partner, joint venturer, or servant of the other. Except as specifically set forth
herein, no party shall have nor exercise any control or direction over the methods by which the other party performs work or obligations
under this Agreement. Further, nothing in this Agreement is intended to create any partnership, joint ventures, lease, or equity
relationship, expressly or by implication, among those parties.

 

19.
Clinical Trial Registry

 

Prior
to enrollment of the first subject in the Study, Sponsor will register the Study on www.clinicaltrials.gov in accordance with
the requirements of the International Committee of Medical Journal Editors (ICMJE) and Public Law 110-85. Results of this Study
will be reported in compliance with applicable laws.

 

20.
Non-Referral/ Anti-Corruption Language

 

20.1.
Institution and CRO, on behalf of Sponsor, agree that it is not their intent under this Agreement to induce or encourage the unlawful
referral of subjects or business between the Parties, and there shall not be any requirement under this Agreement that those parties,
their employees or affiliates, including their medical staff, engage in any unlawful referral of subjects to, or order or purchase
products or services from, one of those parties.

 

20.2.
Institution and CRO, on behalf of Sponsor, agree that their employees, who are involved in the conduct of the Study, will not
offer, pay, request or accept any bribe, inducement, kickback or facilitation payment, and shall not make or cause another to
make any offer or payment to any individual or entity for the purpose of influencing a decision for the benefit of one of those
parties.

 

21.
Force Majeure

 

If
either Party hereto shall be delayed or hindered in, or prevented from, the performance of any act required hereunder for any
reason beyond such Party’s direct control, including but not limited to, strike, lockouts, labor troubles, governmental
or judicial actions or orders, riots, insurrections, war, acts of God, inclement weather, or other reason beyond the Party’s
control (a “Disability”) then such Party’s performance shall be excused for the period of the Disability. Any
Study timelines affected by a Disability shall be extended for a period equal to the delay and any affected Budget shall be adjusted
to account for cost increases or decreases resulting from the Disability. The Party affected by the Disability shall notify the
other Party of such Disability as provided for herein.

 

    	11

    	 

    

 

22.
Counterparts

 

This
Agreement may be executed in any number of counterparts, each of which shall be an original and all of which together shall constitute
one and the same document, and is binding on all Parties notwithstanding that each of the Parties may have signed different counterparts.
Facsimiles or scanned copies of signatures or electronic images of signatures shall be considered original signature unless prohibited
by applicable law.

 

23.
Debarment

 

The
Institution certifies that to its knowledge neither it, nor any of its employees, agents or other persons performing the Study
under its direction, is currently debarred, suspended, or excluded under the Federal Food, Drug and Cosmetic Act, as amended,
or disqualified under the provisions of 21 CFR §312.70. In the event that the Principal Investigator or any Study personnel
becomes debarred or disqualified during the term of this Agreement or within 1 year after termination of the Study, the Institution
agrees to promptly notify CRO after learning of such event. Institution certifies that it is not excluded from a federal health
care program, including Medicare and Medicaid. In the event an Institution becomes excluded during the term of this Agreement
or within 1 year after termination of the Study, the Institution agrees to promptly notify CRO after learning of such event.

 

24.
Choice of Law -Intentionally omitted

 

25.
Entire Agreement

 

Section
and clause headings are used herein solely for convenience of reference and are not intended as substantive parts of the Parties’
agreement. This ACTA incorporates the Exhibits referenced herein. This written ACTA constitutes the entire agreement between the
Parties concerning the subject matter, and supersedes all other or prior agreements or understandings, whether written or oral,
with respect to that subject matter. Any changes made to the terms, conditions or amounts cited in this ACTA require the written
approval of each Party’s authorized representative.

 

The
authorized representatives of the Parties have signed this ACTA as set forth below.

 

	Cancer
    Center of Kansas, P.A.	 	Cancer
    Insight, LLC
	 	 	 	 	 
	By:	 	 	By:	 
	Name:	Shaker
    Dakhil	 	Name:	Steven
    White
	Title:	President	 	Title:	COO
	Date:	4/23/2018	 	Date:	4/23/2018

 

    	12

    	 

    

 

READ
AND ACKNOWLEDGED

 

	By:	 	 
	Name:	Shaker
    Dakhil	 
	Title:	Principal
    Investigator	 
	Date:	4/23/2018	 

 

    	13

    	 

    

 

EXHIBIT
A

PROTOCOL

 

See
attached and incorporated master Protocol, which is identified as Protocol BRI-ROL-001.

 

    	14

    	 

    

 

EXHIBIT
B

BUDGET

 

	A.	This
    Budget has been negotiated at fair and reasonable value. Institution has not been influenced to participate in this Study
    based on financial or other inducements from Sponsor. The compensation may be used at the discretion of Institution to offset
    the costs of the Study. For Study subject visit and Study conduct reimbursements, an item listed herein will be considered
    payable upon Institution’s complete and accurate data entry into the applicable electronic data capture system (EDC)
    of all assessments associated with that visit in the EDC.
	 	 
	B.	Sponsor
    will not be liable for any payment in excess of the fees and costs provided herein except upon Sponsor’s prior written
    agreement. Institution may submit to Sponsor a revised budget requesting additional funds at such time as expenses may reasonably
    be projected to exceed the fees and costs provided herein.
	 	 
	C.	The
    compensation per Study subject will be earned by Institution and made payable by Sponsor as follows:

 

	 	i.	$2,500.00
    will be paid upon completion of the baseline visit, as defined by the Protocol;
	 	 	 
	 	ii.	$2,500.00
    will be paid upon completion of Cycle One, as defined by the Protocol;
	 	 	 
	 	iii.	$2,500.00
    will be paid upon completion of Cycle Two, as defined by the Protocol;
	 	 	 
	 	iv.	$2,500.00
    will be paid upon completion of Cycle Three, as defined by the Protocol;
	 	 	 
	 	v.	$2,500.00
    will be paid upon completion of Cycle Four, as defined by the Protocol;
	 	 	 
	 	vi.	$2,500.00
    will be paid upon completion of Cycle Five, as defined by the Protocol;
	 	 	 
	 	vii.	$2,500.00
    will be paid upon completion of Cycle Six, as defined by the Protocol;
	 	 	 
	 	viii.	$2,500.00
    will be paid upon completion of Cycle Seven, as defined by the Protocol;
	 	 	 
	 	ix.	$2,500.00
    will be paid upon completion of Cycle Eight, as defined by the Protocol;
	 	 	 
	 	x.	$2,500.00
    will be paid upon completion of Cycle Nine, as defined by the Protocol;
	 	 	 
	 	xi.	$2,500.00
    will be paid upon completion of Cycle Ten, as defined by the Protocol;
	 	 	 
	 	xii.	$2,500.00
    will be paid upon completion of Cycle Eleven, as defined by the Protocol;
	 	 	 
	 	xiii.	$2,500.00
    will be paid upon completion of Cycle Twelve, as defined by the Protocol;
	 	 	 
	 	xiv.	$2,500.00
    will be paid upon completion of Cycle Thirteen, as defined by the Protocol;

 

    	15

    	 

    

 

	 	xv.	$2,500.00
    will be paid upon completion of Cycle Fourteen, as defined by the Protocol;
	 	 	 
	 	xvi.	$2,500.00
    will be paid upon completion of Cycle Fifteen, as defined by the Protocol;
	 	 	 
	 	xvii.	$2,500.00
    will be paid upon completion of Cycle Sixteen, as defined by the Protocol;
	 	 	 
	 	xviii.	$2,500.00
    will be paid upon completion of Cycle Seventeen, as defined by the Protocol;
	 	 	 
	 	xix.	$2,500.00
    will be paid upon completion of the final assessment follow-up visit, as defined by the Protocol.

 

	D.	Start-up
    funding will be provided in the amount of $8,500.00 and payable upon execution of the Agreement, which may be used at the
    discretion of Institution to offset the costs of the Study.
	 	 
	E.	Where
    Institution utilizes Western IRB (“WIRB”) as their central IRB, Cancer Insight will pay for WIRB costs directly
    and Institution may direct WIRB to invoice Cancer Insight directly.
	 	 
	F.	Annual
    maintenance funding will be provided in the amount of $2,500.00, which may be used at the discretion of Institution to offset
    the costs of the Study. This amount shall be due beginning in the second year of the Study and shall continue until completion
    of the Study. The annual term shall be determined by the Effective Date of the Agreement.
	 	 
	G.	Institution
    will be using the central IRB designated by Sponsor for the Study. Sponsor or CRO will pay Institution’s IRB fees directly
    to the central IRB and will not reimburse Institution for IRB fees incurred in connection with the Study.
	 	 
	H.	For
    those Subjects who have signed an informed consent, undergone all screening procedures pursuant to the Protocol and are subsequently
    not eligible for the Study (“Screen Failures”), Sponsor will reimburse Institution for up to four (4) Screen Failures
    at a rate of $2,500.00 per Screen Failure, which represents Institution’s personnel costs and screening procedures.
    In the event Institution reaches this maximum number of Screen Failures, Institution shall contact Sponsor or CRO for authorization
    prior to continuing screening.
	 	 
	I.	Sponsor
    will reimburse Institution for additional Study procedures that are deemed to be non standard of care or otherwise not covered
    by a particular Subject’s insurance and that are required by the Protocol, up to a maximum specified in the Protocol
    Payments for such Study procedures will be paid up to the following rates (which include overhead charges):

 

	Procedure or Scan	 	Unit Cost
	MUGA including interpretation and report	 	$	1,679.00	 
	Chest x-ray including interpretation and report, up to	 	$	311.00	 
	CT Scan (chest, abdomen and pelvis) with contrast including interpretation and report	 	$	2,858.00	 
	MRI with contrast including interpretation and report	 	$	4,845.00	 
	PET scan including interpretation and report	 	$	5,371.00	 
	Bone scan including interpretation and report	 	$	1,675.00	 
	Bilateral mammogram including interpretation and report	 	$	719.00	 

 

    	16

    	 

    

 

	J.	Sponsor
    will provide pembrolizumab (KEYTRUDA®, anti-PD-1) and ipilimumab (YERVOY®, anti CTLA-4), as
    applicable. Ipilimumab treatment is limited to four doses. For pembrolizumab, dosing may continue until disease progression,
    unacceptable toxicity, and/or up to twenty-four (24) months in Study subjects without disease progression.
	 	 
	K.	Sponsor
    will provide Interferon-Alpha, BriaVax, DTH (BriaTest), Anergy tests (Candin), and cyclophosphamide Study drugs.
	 	 
	L.	In
    the event any Protocol-required study drugs are provided by Institution through their pharmacy or other means, the cost of
    such shall be invoiceable by Institution and paid by Sponsor.
	 	 
	M.	Invoicing
    shall be conducted no more frequently than monthly. Invoices should be sent to Cancer Insight via email to Steven White at
    swhite@cancerinsight.com. In the event that such method of delivery is rendered impossible or impractical, invoices may be
    sent to Cancer Insight via mail to:

 

	 	Cancer
    Insight, LLC
	 	Attn:
    Steven R. White
	 	110
    East Houston Street, Floor 7
	 	San
    Antonio, Texas 78205

 

	N.	Payments
    will be sent no later than thirty (30) days from receipt and approval of invoices. Payments will be issued via electronic
    funds transfer whenever possible and under the following instructions:

 

Bank
Name: Crossfirst Bank

Account
Number: 201100533

Routing
Number: 101015282

 

In
the event that such method of payment is rendered impossible or impractical, payments will be issued via check and mailed to the
address included on the associated invoice.

 

    	17

    	 

    

 

EXHIBIT
C

ADMINISTRATIVE
AND STUDY POINTS OF CONTACT

 

CRO
Clinical Department Point of Contact:

 

Karen
Arrington

karrington@cancerinsight.com

 

CRO
Regulatory Department Point of Contact:

 

Susie
Hargrove

shargrove@cancerinsight.com

 

CRO
Administrative and Billing Department Point of Contact:

 

Steven
White

swhite@cancerinsight.com

 

    	18

    	 

    

 

EXHIBIT
D

LETTER
OF INDEMNIFICATION (LOI)/SUBJECT INJURY

 

INSTITUTION:
Cancer Center of Kansas, P.A. (the “Institution”)

 

TITLE
OF CLINICAL TRIAL: “A Phase I/IIa Study of the Whole-Cell Vaccine BriaVaxTM in Metastatic or Locally Recurrent Breast Cancer
Patients”

 

CRO:
Cancer Insight, LLC

 

STUDY
NUMBER: BRI-ROL-001

 

	1)	Institution
    has entered into an Accelerated Clinical Trial Agreement (ACTA) with CRO to participate in the above sponsored Study. CRO
    has been engaged by BriaCell Therapeutics Corp. (the “Sponsor”) to arrange and administer this BriaCell Therapeutics
    Corp. sponsored multi-center clinical trial.
	 	 
	2)	Sponsor
    has delegated to CRO responsibility for the management and monitoring of this Study. Sponsor has further authorized CRO to
    bind Sponsor to its obligations within the Accelerated Clinical Trial Agreement for this Study executed between CRO and Institution.
    Sponsor accepts responsibility for its obligations contained in that Accelerated Clinical Trial Agreement.
	 	 
	3)	Institution
    agrees to participate by allowing the Study to be undertaken utilizing such facilities, personnel and equipment as Institution
    may reasonably need for its conduct of the Study.
	 	 
	4)	In
    consideration of such participation by Institution, and subject to paragraph 5 below, the Sponsor shall defend, indemnify,
    and hold harmless the Institution and its medical affiliates and affiliated hospitals, and each of their trustees, officers,
    directors, governing bodies, subsidiaries, affiliates, investigators, employees, IRB members, agents, successors, heirs and
    assigns (collectively referred to as “Institution’s Indemnitees”), from and against any third party claims,
    loss, damage, cost and expense of claims (including reasonable attorney’s fees) and suits (“Claims”), alleged
    to be caused by or arising from the conduct of the Study or use of the Study Drug or Study Device under this Agreement or
    from the use of the Study results, regardless of the legal theory asserted.
	 	 
	5)	Sponsor
    shall have no obligation to provide such indemnification to the extent that such Claim is solely caused by Institution’s
    Indemnitee(s)’: (1) failure to adhere to and comply with all material and substantive specifications and directions
    set forth in the Protocol (except to the extent such deviation is reasonable to protect the rights, safety and welfare of
    the Study subjects); (2) failure to comply with all applicable laws and regulations in the performance of the Study; or (3)
    if such claim is directly caused by the negligent acts or omissions of Institution’s Indemnitees(s).
	 	 
	6)	Subject
    to the limits and without waiving any immunities provided under applicable law (including constitutional provisions, statutes
    and case law) regarding the status, powers and authority of the Institution or the Institution’s principal(s), Institution
    shall indemnify, hold harmless and defend Sponsor, its directors, officers, employees and agents, (“Sponsor’s
    Indemnitees”) from and against only those third-party Claims to the extent directly attributable to Institution’s
    negligence in its conduct of the Study. Notwithstanding the above, Institution shall have no obligation to indemnify Sponsor
    for any other Claims (including, but not limited to, infringement or product liability Claims).

 

    	19

    	 

    

 

	7)	The
    indemnified party shall give notice to the indemnifying party promptly upon receipt of written notice of a Claim for which
    indemnification may be sought under this Agreement, provided, however, that failure to provide such notice shall not relieve
    indemnifying party of its indemnification obligations except to the extent that the indemnifying party’s ability to
    defend such Claim is materially, adversely affected by such failure. Indemnifying party shall not make any settlement admitting
    fault or incur any liability on the part of the indemnified party without indemnified Party’s prior written consent,
    such consent not to be unreasonably withheld or delayed. The indemnified Party shall cooperate with indemnifying Party in
    all reasonable respects regarding the defense of any such Claim, at indemnifying Party’s expense. The indemnified Party
    shall be entitled to retain counsel of its choice at its own expense. In the event a Claim falls under this indemnification
    clause, in no event shall the indemnified Party compromise, settle or otherwise admit any liability with respect to any Claim
    without the prior written consent of the indemnifying Party, and such consent not to be unreasonably withheld or delayed.
	 	 
	8	EXCEPT
    FOR THE PARTIES’ OBLIGATIONS TO INDEMNIFY EACH OTHER AS STATED ABOVE, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY
    FOR SPECIAL, CONSEQUENTIAL OR INCIDENTAL DAMAGES ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, EVEN IF ADVISED OF THE
    POSSIBILITY OF THE SAME.
	 	 
	9)	If
    a Study subject suffers an adverse reaction, illness, or injury which, in the reasonable judgment of Institution, was directly
    caused by a Study Drug or Study Device or any properly performed procedures required by the Protocol, Sponsor shall reimburse
    for the reasonable and necessary costs of diagnosis and treatment of any Study subject injury, including hospitalization,
    but only to the extent such expenses are not attributable to: (i) Institution’s negligence or willful misconduct; or
    (ii) the natural progression of an underlying or pre-existing condition or events, unless exacerbated by participating in
    the Study.
	 	 
	10)	Sponsor
    shall, at its sole cost and expense, procure and maintain commercial general liability insurance, clinical trial insurance
    and products liability insurance or equivalent self-insurance, unless otherwise indicated in an attachment, in amounts not
    less than $5,000,000.00 per occurrence and $5,000,000.00 annual aggregate. Such commercial general liability insurance, clinical
    trial insurance and products liability insurance or equivalent self-insurance shall provide contractual liability coverage
    for Sponsor’s indemnification obligations herein.
	 	 
	11)	Upon
    written request, Sponsor will provide evidence of its insurance policy or a program of self insurance and will provide Institution
    with written notice of any material change in its coverage which would affect Sponsor’s ability to meet its obligations
    under this Agreement. Sponsor’s inability to meet its insurance obligation constitutes material breach of this LOI and
    the Accelerated Clinical Trial Agreement executed with the CRO for this Study.
	 	 
	12)	During
    the Study and for at least two (2) years following the completion of the Study at all sites, Sponsor shall promptly provide
    Institution and Principal Investigator with the written report of any findings, including Study results and any routine monitoring
    findings in site monitoring reports, and data safety monitoring committee reports including, but not limited to, data and
    safety analyses, and any Study information that may (i) affect the safety and welfare of current or former Study subjects,
    or (ii) influence the conduct of the Study. Institution and/or Principal Investigator will communicate findings to the IRB
    and Study subjects, as appropriate.

 

    	20

    	 

    

 

	13	Except
    as permitted in Article 10.3 in the ACTA, neither Institution nor Sponsor may use the name, trademark, logo, symbol, or other
    image or trade name of any other party or their employees and agents in any advertisement, promotion, or other form of publicity
    or news release or that in any way implies endorsement without the prior written consent of an authorized representative of
    the other party whose name is being used. Such approval will not be unreasonably withheld.

 

The
authorized representatives have signed this Letter of Indemnification as set forth below.

 

	Cancer
    Center of Kansas, P.A.	 	BiraCell
    Therapeutics Corp.
	 	 	 	 	 
	By:	 	 	By:	 
	Name:	Shaker
    Dakhil	 	Name:	William
    V. Williams
	Title:	President	 	Title:	President
    and CEO
	Date:	4/23/2018	 	Date:	4/23/2018

 

	READ AND ACKNOWLEDGED	 	 
	 	 
	By:	 	 	 
	Name:	Shaker
    Dakhil	 	 
	Title:	Principal
    Investigator	 	 
	Date:	4/23/2018	 	 

 

    	21Amendment
No. 2 to UNIVERSITY Agreement No. S15-00193V

 

	Parties to this Amendment:	 	The Regents of the University
    of California, acting for and on behalf of University of California, Davis Health (“UNIVERSITY”).
	 	 	 
	 	 	and
	 	 	 
	 	 	Briacell Therapeutics Corp. (“COMPANY”).
	 	 	 
	Original Agreement:	 	Agreement for Services
	 	 	(UNIVERSITY Agreement No. S15-00193V)
	 	 	(“Agreement”).
	 	 	 
	Effective Date of
    this Amendment:	 	Date of Last Signature
    Below.

 

WHEREAS
the Agreement was to have expired on June 9, 2017; however the parties have continued to perform in accordance with the terms
of the Agreement and desire to acknowledge and substantiate the oral extension of the Agreement.

 

NOW,
THEREFORE, for good and valuable consideration, the parties agree that said Agreement is amended as follows:

 

	 	1.	Defined Terms.
    Capitalized terms used but not defined herein shall have the respective meanings ascribed to such terms in the Agreement.
	 	 	 
	 	2.	Amendment(s)
    to the Agreement,

 

	 	A.	Section 1, Term,
    of the Agreement shall be revised to read as follows:

 

“The
term ofthis Agreement shall commence on June 10, 2015 (the “Effective Date”), and shall continue through July 1, 2020,
unless earlier terminated, and may be extended by mutual -written agreement of the Parties. “

 

	 	B.	The Preamble shall
    be revised to read as follows:

 

“This
Agreement for Services (“Agreement”) is made by and between The Regents of the University of California, a California
constitutional corporation, acting for and on behalf of University of California, Davis Health (“UNIVERSITY”), and
Briacell Therapeutics Corp., a private California corporation, (“COMPANY”). UNIVERSITY and COMPANY are referred to
individually as a “Party” and collectively as the “Parties “.

 

WHEREAS,
COMPANY desires that UNIVERSITY’S Institute of Regenerative Cures provide GMP Facility and Stem Cell Program core services
for the purpose of manufacturing cell-based vaccine (BriaVax XV-BR-l-GM) and control cell line and IND- enabling studies and regulatory
services for COMPANY’S FDA submission;

 

WHEREAS,
UNIVERSITY is fully qualified and desires to provide such services to COMPANY;

 

    	Page 1 of 9

     

    

 

Amendment
No. 2 to UNIVERSITY Agreement No. S15-00193V

 

WHEREAS,
UNIVERSITY has determined that the provision of such services shall not adversely affect the conduct of UNIVERSITY activities;
and

 

WHEREAS,
UNIVERSITY has determined that furnishing of services requested by COMPANY is consistent with one or more of UNIVERSITY’S
missions.

 

THEREFORE,
the Parties agree to the terms and conditions contained herein. “

 

	 	C.	As of the Effective Date
    of this Amendment, Exhibit A (Scope of Work and Budget) of the Agreement shall be deleted and replaced in its entirety by
    revised Exhibit A (Scope of Work and Budget), attached hereto and incorporated herein.
	 	 	 
	 	D.	The Parties acknowledge the UNIVERSITY’S
    name change as follows:

 

“The
Regents of the University of California, a California constitutional corporation, acting for and on behalf of its University of
California, Davis Health System to The Regents of the University of California, a California constitutional corporation, acting
for and on behalf of University of California, Davis Health. “

 

	 	E.	All other terms and conditions
    shall remain the same.

 

	 	3.	Ratification of the Agreement.
    Except as expressly set forth in this Amendment, the Agreement shall remain unmodified and in full force and effect.
	 	 	 
	 	4.	Counterparts. This Amendment may be executed
    in counterparts, each of which shall be deemed to be an original, but all of which constitute one instrument. In the event
    that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf’ format data file,
    such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed)
    with the same force and effect as if such facsimile or “.pdf’ signature page were an original thereof.

 

IN
WITNESS WHEREOF, the duly authorized representatives of UNIVERSITY and COMPANY have executed this Amendment No. 2 as of the last
date of signature written below.

 

AGREED:

 

	THE
    REGENTS OF THE UNIVERSITY OF CALIFORNIA ON BEHALF OF UNIVERSITY OF CALIFORNIA DAVIS HEALTH	 	BRIACELL THERAPEUTICS CORP.

 

	 	 	 	 	 
	By		 	By	
	 	Annie
    Wong	 	 	William Williams, MD
	 	Director, UC Davis
    Health Contracts	 	 	President & CEO
	 	 	 	 	Corporate Office - US
	 	 	 	 	 
	Date	8.27.2018	 	Date	2018
    August 24

 

    	Page 2 of 9

     

    

 

Amendment
No. 2 to UNIVERSITY Agreement No. S15-00193V

 

EXHIBIT
A

SCOPE
OF WORK AND BUDGET

 

I.
SCOPE OF WORK

 

UNIVERSITY’S
Institute of Regenerative Cures shall provide GMP Facility and Stem Cell Program core services to COMPANY for the purpose of manufacturing
cell-based vaccine (BriaVax SV-BR-l-GM) and control cell line and IND-enabling studies and regulatory services for COMPANY’S
FDA submissions (‘‘Services’’).

 

1.
PROJECT 1

 

A.
UNIVERSITY GMP manufacturing of a cell-based vaccine (BriaVax SV-BR-l-GM) and a control cell line scope of work and cost estimates
given to COMPANY’S employee on May 14, 2015:

 

Corporate
Office – US

Briacell
Therapeutics Corp.

820
Heinz Avenue

Berkeley,
CA 94710

Tel:
888-485-6340

FAX:
424-245-3719

 

Dr.
Charles L. Wiseman

Chairman
and CEO

Briacell
Therapeutics Corp.

8900
Wilshire Blvd. Suite 310

Beverly
Hills, CA 90211

Mobile:
323-377-4741

Email:
cw@briacell.com

 

B.
Work associated with the Services:

 

Transfer
of technology and procedures from BriaCell to the UC Davis GMP Facility.

 

Generation of GMP Standard Operating Procedures (SOPs).

 

Manufacturing
and cryopreservation of the vaccine cell line (400 vials with 15 million cells/vial).

 

Manufacturing
and cryopreservation of the control cell line (100 vials with 2 million cells/vial).

 

Quality
control and release tests on the cells, generation of appropriate documentation.

 

Storage of the cryopreserved vaccine and control
cell line vials for 1 year.

 

Shipping
of the vaccine and control cell line vials (4 shipments estimated).

 

    	Page 3 of 9

     

    

 

Amendment
No. 2 to UNIVERSITY Agreement No. S15-00193V

 

2.
PROJECT 2

 

A.
UNIVERSITY Stem Cell Program’s IND-enabling studies and regulatory assistance with COMPANY’S FDA submissions scope
of work and cost estimates given to COMPANY’S employee on April 6, 2017:

 

Markus
Lacher, Ph.D.

Chief
Scientific Officer

Sapientia
Pharmaceuticals, Inc.

Corporate
and R&D Lab

820
Heinz Avenue

Berkeley,
CA 94710

 

B.
Work associated with the Services:

 

The
estimate cost for the proposed IND- enabling studies and for regulatory Assistance for FDA documents and submission are:

 

Institute
for Regenerative Cures Stem Cell Core:

 

	 	●	Production of cells
	 	●	Irradiation of cells
	 	●	Generation of formulations (Lactated Ringer’s,
    CryoStor with 2, 2.5, 5, 10% DMSO)
	 	●	Assessment of cell viability
	 	●	Potency testing (GM-CSF)
	 	●	Preparation of cells for flow cytometry (BrdU
    incorporation/PI staining after irradiation)
	 	●	“Immune Signature” assessment by
    quantitative RT-PCR (≤ 24 genes)
	 	●	Budget for off-the-shelf TaqMan reagents for
    26 genes (2 controls/references)

 

Reagents: https://www.thermofisher.com/us/en/home/life-science/pcr/real-time-pcr/real-time-
pcr-assays/taqman-gene-expression.html

 

Institute
for Regenerative Cures Mouse Core (immune-deficient):

 

	 	●	Production of cells
	 	●	Tumorigenicity testing of formulations: Animals
    for Biosafety: Experimental mice (NOD.Cg- Prkdcscid I12rgtm1Wjl/SzJ (NOD/SCID/IL2RG -/- AKA
    NSG)

 

	 	○	2
    pos controls, SV-BR-l-GM + Reh cell line
	 	○	2
    neg controls Lactated Ringers and CS10 (10% DMSO) (Lactated Ringers + high concentration of DMSO)
	 	○	5
    Formulations
	 	○	4
    mice/test article, injections on each side
	 	○	32
    mice, housed for 4 months

 

	 	●	Pathology at UC Davis Comparative
    Pathology Laboratory

 

    	Page 4 of 9

     

    

 

Amendment
No. 2 to UNIVERSITY Agreement No. S15-00193V

 

Institute
for Regenerative Cures Mouse Core (immune-deficient):

 

	 	●	Tumorigenicity
    testing of formulations: Experimental mice (NOD.Cg-Prkdcscid I12rgtmlwj1/SzJ (NOD/SCID/IL2RG -/- AKA
    NSG)

 

	 	○	2 pos controls, SV-BR-l-GM
    + Reh cell line
	 	○	2 neg controls Lactated Ringers and CS10 (10%
    DMSO) (Lactated Ringers + high concentration of DMSO)
	 	○	5 Formulations
	 	○	3 mice/test article,
    injections on each side
	 	○	2 time-points for
    harvest (2 weeks and 1 month),
	 	○	Per time point:
    27 mice
	 	○	Total (2 time points): 54 mice

 

	 	●	Assessment of skin pathology
    following intramuscular inoculation of formulations: Visual assessment daily Days 1 -7, then weekly.
	 	●	In vivo vaccine cell replication mice housed
    for 2 weeks (cohort 1) and 1 month (cohort 2) and then injection site assessed for Human vs Murine PCR in immune-compromised
    mice.

 

Specific
Aim #1: Evaluation of stability of cells over time following freezing immediately after irradiation. $54.328

 

Summary

 

Cells
will be frozen immediately after irradiation in 2%, 2.5%, 5%, or 10% DMSO as CryoStor (BioLife Solutions, Bothell, WA)-based formulations.
To evaluate stability, cells will be thawed out at various time points following freezing (1, 2, or 4 days, 1 or 2 weeks, 1, 2,
3, 6 months). Cells will be brought in culture following thawing, and cell viability and GM-CSF production will be evaluated.
Expression of the immune signature will be evaluated in selected preparations and compared to cells of the current, 2-step, manufacturing
process, i.e., to cells that are resuspended in Lactated Ringer’s solution following irradiation and are not cryopreserved
thereafter.

 

Stability
of cells resulting from both new formulations and the current manufacturing process will be assessed.

 

Estimated
Cost of Materials: $25,636

Estimated
Cost of Technician Time: $23,112

Estimated
Cost of Study Plan and

Study
Report: $5,580

 

Specific
Aim #2: Evaluation of stability of cells over time following culturing of irradiated cells and freezing. $54.797

 

Summary

 

While
Specific Aim 1 is directed to New Formulations generated immediately upon irradiation, this Specific Aim 2 includes a short-term
culturing step after irradiation. Following irradiation, cells will be cultured for 2-3 days. Adherent cells will be selected
and frozen in 2%, 2.5%, 5%, or 10% DMSO. To evaluate stability, cells will be thawed out at various time points following freezing
(1, 2, or 4 days, 1 or 2 weeks, 1, 2, 3, 6 months). Cells will be brought in culture following thawing and evaluated for viability
and GM-CSF production. Expression of the immune signature will be evaluated in selected preparations and compared to cells of
the current manufacturing process, i.e., to cells that were cryopreserved without prior irradiation. Stability of cells resulting
from both new formulations and the current 2-step manufacturing process will be assessed. The methods are identical to those of
Specific Aim 1.

 

Estimated
Cost of Materials: $26,033

Estimated
Cost of Technician Time: $23,184 Estimated Cost of Study Plan and Study Report: $5,580

 

    	Page 5 of 9

     

    

 

Amendment
No. 2 to UNIVERSITY Agreement No. S15-00193V

 

Specific
Aim #3: Evaluation of replication incompetence of formulated cells $122.404

 

Summary

 

As
an important safety aspect, irradiated cells formulated as indicated under Specific Aims #1 and #2 will be assessed for cell replication
before cryopreservation and upon thawing This aim will consist of 2 steps:

 

	 	1.	Cells will be cultured and
    5-bromo-2’-deoxyuridine (BrdU) added. Cells will be harvested and assessed by flow cytometry for BrdU incorporation
    to assess cell replication and for propidium iodide (PI) fluorescence to establish cell cycle profiles at the time of harvest.
	 	 	 
	 	2.	Cells
    will be injected into immune-compromised (NOD.Cg-Prkdcscid I12rgtmlWjl/SzJ (NOD/SCID/IL2RG -/-
    AKA NSG)) mice and assessed for xenograft tumor formation and in situ cell replication, the latter assessed by qPCR.

 

Methods:

 

To
assess the potential for cell replication, up to 4 formulations (up to 2 formulations each from Aim #1 and Aim #2) considered
particularly stable as determined by the criteria outlined under Aims #1 and #2 will be subjected to in vitro (1) and in
vivo (2) tests. (1) Institute for Regenerative Cures Stem Cell Core and Flow Cytometry Shared Resource core facility: The
formulations will be thawed and cultured for 2-4 days in (serum-containing) full medium (PRMI-1640 with 10% FBS and GlutaMAX)
with the last 24 hours containing 5-bromo-2’-deoxyuridine (BrdU). Thereafter, the cells will be processed through the EZ-BrdU
kit (Tonbo Bioscences, San Diego, CA) and analyzed by flow cytometry for BrdU incorporation (cell proliferation) and propidium
iodide fluorescence intensity (cell cycle stage). Non-irradiated SV-BR-l-GM (BriaVax) cells will serve as positive control. (2)
Institute for Regenerative Cures Mouse Core (immune- deficient): Assessment of cell replication potential in NOD-scid gamma (NSG)
mice. A. Xenograft tumor substudy: New formulations will be subcutaneously injected as 2.5-3 million cells (admixed with matrigel)
per injection site. The animals will be followed for up to 4 months with caliper-based tumor measurements (if applicable) then
submitted to the UC Davis Comparative Pathology Laboratory for tissue excision and H&E staining to assess potential microscopic
tumor formation. As positive controls, non-irradiated SV-BR-l-GM cells and the Reh cell line will be selected. As negative controls,
Lactated Ringer’s solution and CS10 freeze medium, both without cells, will be used. B. In situ cell replication
substudy: New formulations will be intramuscularly injected as 2.5-3 million cells (admixed with matrigel) per injection site.
The animals will be followed for 2 weeks (cohort 1) or 1 month (cohort 2), then the tissues of the injection sites excised and
submitted to the Institute for Regenerative Cures Stem Cell Core for genomic DNA extraction and qPCR to quantify the amount of
human DNA (derived from the BriaVax cells).

 

    	Page 6 of 9

     

    

 

Amendment
No. 2 to UNIVERSITY Agreement No. S15-00193V

 

In
vitro cell replication (BrdU/PI. flow cytometry):

 

Estimated
Cost of Materials: $12,140

Estimated
Cost of Technician Time: $8,064

Estimated
Cost of Study Plan and Study Report: $5,580

 

In
vivo study:

 

Estimated
Cost of Materials: $22,368

Estimated
Cost of Technician Time: $57,512

Estimated
Cost of Study Plan and Study Report: $16,740

 

Regulatory
Support preparing FDA documents and FDA submission

Estimated
Cost: up to 100 hours $12,500.00

 

Overall
Total with Regulatory; $244.029

 

II.
COMPENSATION

 

1.
PROJECT 1

 

A. Rates

 

Approved
GMP facility rate for non UC customers: $500 / hour

 

Transfer
of technology and procedures from BriaCell to the UC Davis GMP facility:

 

GMP
facility time required: 2 hours = $1,000

 

Generation
of GMP Standard Operating Procedures (SOPs):

 

GMP
facility time required: 4 hours = $2,000

 

Manufacturing
and cryopreservation of the vaccine cell line (400 vials with 15 million cells / vial):

 

GMP
facility time required: 24 hours = $12,000

 

Manufacturing
and cryopreservation of the control cell line (100 vials with 2 million cells / vial):

 

GMP
facility time required: 8 hours = $4,000

 

Quality
control and release tests on the cells, generation of appropriate documentation:

 

14
day sterility assay (21 CFR) for outside customers: $120.79 per assay

LAL
Endotoxin assay for outside customers: $358.52 per assay

Mycoplasma
PCR for outside customers: $250 per assay

 

14
day sterility on the vaccine cell line:

 

1
assay on incoming master cell bank, 4 assays as release tests (1 percent of the final product vials), 5 assays total: $603.95

 

    	Page 7 of 9

     

    

 

Amendment
No. 2 to UNIVERSITY Agreement No. S15-00193V

 

14
day sterility on the control cell line:

 

1
assay on incoming master cell bank, 1 assay as release test (1 percent of the final product vials), 2 assays total: $241.58

 

LAL
Endotoxin assay on the vaccine cell line:

 

1
assay on incoming master cell bank, 4 assays as release tests (1 percent of the final product vials), 5 assays total: $1,792.60

 

LAL
Endotoxin assay on the control cell line:

 

1
assay on incoming master cell bank, 1 assay as release test (1 percent of the final product vials), 2 assays total: $717.04

 

Mycoplasma
PCR on the vaccine cell line:

 

1
assay on incoming master cell bank, 4 assays as release tests (1 percent of the final product vials), 5 assays total: $1250.95

 

Mycoplasma
PCR on the control cell line:

 

1
assay on incoming master cell bank, 1 assay as release test (1 percent of the final product vials), 2 assays total: $500

 

REMARK:
MYCOPLASMA CULTURE (Send out test): TBD, not included in this price quotation.

 

Generation
of appropriate documentation (Certificates of Analysis):

 

GMP
facility time required: 2 hours = $1,000

 

Storage
of the cryopreserved vaccine and control cell line vials:

 

1
year of storage: GMP facility time required: 8 hours = $4,000

 

Shipping
of the vaccine and control cell line vials:

 

GMP
facility time required per shipment (including chain of custody documentation): 1 hour = $500

 

Shipping
cost through Fedex: Dependent on shipment size, but estimated at $350 per shipment.

 

4
shipments estimated: GMP facility time: $2,000, Fedex charge: $1,400.

 

Estimated
materials and reagents costs:

 

Media,
Fetal Bovine Serum, glutamine, flasks, plasticware, other disposables: $10,000

 

REMARK:
Materials and reagents costs are estimates only and may vary.

 

*Grand
total, including estimated materials and reagents costs: $42,506.12

 

    	Page 8 of 9

     

    

 

Amendment
No. 2 to UNIVERSITY Agreement No. S15-00193V

 

B.
Payment Schedule:

 

UNIVERSITY
shall submit invoices to COMPANY in the amount of Forty Two Thousand Five Hundred Six Dollars and Twelve Cents ($42,506.12). The
payment schedule will take the following form:

 

	A. First upfront payment:	 	$	21,253.06	 
	B. Second payment after completion of Services:	 	$	21,253.06	 
	C. Grand Total*:	 	$	42,506.12	 

 

COMPANY
agrees to remit payments in full by check no later than thirty (30) calendar days from date indicated in said invoices.

 

2.
PROJECT 2

 

A.
Rates

 

*Grand
total with Regulatory; $244.029.00

 

	 	 	Project Cost Estimate
	Quantity	 	Description	 	Cost	 
	1 Experiment	 	Evaluation of stability of cells over time following freezing immediately after irradiation	 	$	54,328	 
	1 Experiment	 	Evaluation of stability of cells over time following culturing of irradiated cells and freezing	 	$	54,797	 
	1 Experiment	 	Evaluation of replication incompetence of formulated cells	 	$	122,404	 
	100 hours	 	Regulatory Consultation	 	$	12,500	 
	 	 	 	 	 	 	 
	 	 	Estimated Total Costs	 	$	244,029	 

 

B.
Payment Schedule:

 

UNIVERSITY
shall submit invoices to COMPANY in the amount of Two Hundred Forty Four Thousand Twenty Nine Dollars and Zero Cents ($244,029.00).
The payment schedule will take the following form or as indicated in said invoices:

 

	A. First upfront payment:	 	$	122,014.50	 
	B. Second payment after completion of Services:	 	$	122,014.50	 
	C. Grand Total*:	 	$	244,029.00	 

 

COMPANY
agrees to remit payments in full by check no later than thirty (30) calendar days from date indicated in said invoices.

 

*UNIVERSITY
reserves the right to review the cost for each manufacturing service, if necessary adjust such costs. Such cost adjustments shall
be communicated by UNIVERSITY to COMPANY at least thirty (30) days in advance.

 

    	Page 9 of 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]